Epitropoulos Alice T, Weiss Jamie L
Ophthalmic Surgeons & Consultants of Ohio, The Eye Center of Columbus, 262 Neil Ave. Suite 430, Columbus, OH, 43215, USA.
ScienceDocs Inc, 28315 Ella Rd, Rancho Palos Verdes, CA, 90275, USA.
Am J Ophthalmol Case Rep. 2022 Jul 2;27:101649. doi: 10.1016/j.ajoc.2022.101649. eCollection 2022 Sep.
To report on the management and effectiveness of treating patients with stage I Neurotrophic Keratitis using an 8-week course of topical recombinant human nerve growth factor (rhNGF, cenegermin).
In this retrospective case series, punctate epithelial erosions (PEE), best corrected visual acuity (BCVA) and corneal sensation were followed and documented from 2 to 12 months in patients treated as per the standard of care. Clinical outcomes including changes in PEEs, corneal sensation and BCVA are reported. Most patients also had preexisting thyroid disease.
All patients had clinically significant improvements in PEE, and corneal sensation. Three of the four patients had a significant improvement in BCVA, one patient had no change in their pre-treatment visual acuity (BCVA 20/20) The four patients studied also reported decreased photophobia and improvements in their quality of life. This case series provides real-world evidence of the safety and efficacy of cenegermin treatment of stage I NK for all four patients.
报告采用为期8周的局部应用重组人神经生长因子（rhNGF，西奈吉明）疗程治疗I期神经营养性角膜炎患者的管理情况及疗效。
在这个回顾性病例系列中，按照护理标准治疗的患者在2至12个月内对点状上皮糜烂（PEE）、最佳矫正视力（BCVA）和角膜感觉进行了跟踪记录。报告了包括PEE变化、角膜感觉和BCVA在内的临床结果。大多数患者还患有甲状腺疾病。
所有患者的PEE和角膜感觉均有临床显著改善。四名患者中有三名的BCVA有显著改善，一名患者的治疗前视力（BCVA 20/20）无变化。所研究的四名患者还报告畏光减轻且生活质量有所改善。该病例系列为西奈吉明治疗所有四名I期NK患者的安全性和有效性提供了真实世界的证据。
